Provided by Tiger Fintech (Singapore) Pte. Ltd.

Kymera Therapeutics, Inc.

31.19
-2.3900-7.12%
Volume:376.02K
Turnover:12.38M
Market Cap:2.03B
PE:-10.46
High:33.51
Open:33.14
Low:30.89
Close:33.58
Loading ...

NAYA Biosciences Announces Nomination of New Board Members

GlobeNewswire
·
19 Feb

Kymera Therapeutics Price Target Maintained With a $60.00/Share by Stephens & Co.

Dow Jones
·
22 Jan

Conviction stock-picking drives biotech success: a biotech market review of 2024

LiveWire
·
17 Jan

Kymera Therapeutics (KYMR) Gets a Buy from Truist Financial

TIPRANKS
·
16 Jan

Bank of America Securities Remains a Hold on Kymera Therapeutics (KYMR)

TIPRANKS
·
16 Jan

Kymera Provides Pipeline Objectives for 2025, Stock Gains

Zacks
·
16 Jan

Kymera Therapeutics (KYMR) Moves 7.8% Higher: Will This Strength Last?

Zacks
·
15 Jan

Kymera Therapeutics Unveils 2025 Strategy and Trials

TIPRANKS
·
15 Jan

Kymera Therapeutics Surges 10% on Bold 2025 Roadmap to Revolutionize Immunology Treatments

GuruFocus.com
·
15 Jan

BRIEF-Kymera Plans To Initiate A KT-621 Phase 1B Trial In Atopic Dermatitis Patients In 2Q25 With Data In 4Q25

Reuters
·
14 Jan

Kymera Therapeutics announces corporate goals for 2025

TIPRANKS
·
14 Jan

Kymera: Plans to Initiate a KT-621 Phase 1B Trial in Atopic Dermatitis Patients in 2Q25 With Data in 4Q25

THOMSON REUTERS
·
14 Jan

Kymera: Well-Capitalized With $850 Mln in Cash and Runway Into Mid-2027

THOMSON REUTERS
·
14 Jan

Kymera: to Initiate Parallel Phase 2B Trials in Ad and Asthma in Late 2025 and Early 2026, Respectively

THOMSON REUTERS
·
14 Jan

Kymera Therapeutics Outlines Key 2025 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs

GlobeNewswire
·
14 Jan

Kymera Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14

GlobeNewswire
·
07 Jan

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Kymera Therapeutics (KYMR) and Sarepta Therapeutics (SRPT)

TIPRANKS
·
02 Jan

Leerink sees positive readthrough for Kymera Therapeutics from J&J-Kaken deal

TIPRANKS
·
27 Dec 2024

Kymera Therapeutics Initiated at Buy by BTIG

Dow Jones
·
11 Dec 2024

Kymera Therapeutics Inc : Btig Initiates Coverage With Buy Rating; Target Price $60

THOMSON REUTERS
·
10 Dec 2024